In recent years, immune checkpoint inhibitors (ICIs) targeting programmed cell death, regarding protein-1 (PD-1), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA4), have become another pillar of cancer treatment. Here, CTLA4 is linked to cancer.